Cargando…

DIPG-79. H3K27M INDUCES EPIGENETIC AND ONCOGENIC CHANGES THAT ARE PARTIALLY REVERSED BY SMALL MOLECULE AURORA KINASE B/C INHIBITION

Diffuse intrinsic pontine glioma (DIPG) is a fatal pediatric brain tumor with no curative treatments. Approximately 80% of DIPGs contain an H3K27M mutation. The implications of the mutation and how they may be targeted are not fully understood. We established an H3K27M effect-isolating model by tran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chatwin, Hannah, Lemma, Rakeb, DeSisto, John, Knox, Aaron, Mestnik, Shelby, Reid, Aidan, Vibhakar, Rajeev, Venkataraman, Sujatha, Green, Adam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Diffuse Midline Glioma/DIPG
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715821/ http://dx.doi.org/10.1093/neuonc/noaa222.121

Ejemplares similares

DIPG-42. TOWARD MULTIMODALITY THERAPY FOR DIPG/DMG: DEVELOPMENT AND INVESTIGATION OF CRANIOSPINAL IRRADIATION AND CONVECTION-ENHANCED DELIVERY PDX MODELS
por: Knox, Aaron J, et al.
Publicado: (2020)

DIPG-56. Development and application of a novel antibody against CD99 as a therapeutic strategy in Diffuse Midline Glioma
por: Venkataraman, Sujatha, et al.
Publicado: (2022)

DIPG-61. Preclinical efficacy of combined radiotherapy with venetoclax treatment in targeting diffuse midline gliomas
por: Madhavan, Krishna, et al.
Publicado: (2022)

DIPG-34. SUPER ELONGATION COMPLEX AS A TARGETABLE DEPENDENCY IN H3K27M+ DIFFUSE MIDLINE GLIOMA
por: Dahl, Nathan, et al.
Publicado: (2020)

DIPG-73. SENESCENCE ASSOCIATED SECRETORY PHENOTYPE AS A MECHANISM OF RESISTANCE AND THERAPEUTIC VULNERABILITY IN BMI1 INHIBITOR TREATED DIPG
por: Balakrishnan, Ilango, et al.
Publicado: (2020)

DIPG-14. TARGETING POLO-LIKE KINASE 1 IN COMBINATION WITH KEY ONCOGENIC DRIVERS IN DIPG: FROM SINGLE AGENT TO COMBINATION STRATEGIES
por: Franshaw, Laura, et al.
Publicado: (2020)

DIPG-74. RE-IRRADIATION OF DIPG: DATA FROM THE INTERNATIONAL DIPG REGISTRY
por: Lafay-Cousin, Lucie, et al.
Publicado: (2020)

DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers
por: Tsai, Jessica W, et al.
Publicado: (2022)

DIPG-16. Evaluation of myeloid component of DIPG microenvironment
por: Mishra, Deepak, et al.
Publicado: (2022)

DIPG-03. Therapeutic targeting of purine biosynthesis in DIPG
por: Mersich, Ian, et al.
Publicado: (2022)

DIPG-22. DISSECTING THE ONCOGENIC ROLE OF FOXR2 IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: Tsai, Jessica W, et al.
Publicado: (2020)

DIPG-46. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW
por: Lazow, Margot A, et al.
Publicado: (2020)

DIPG-20. DETERMINATION AND MANAGEMENT OF HYDROCEPHALUS IN PATIENTS WITH DIPG, AN INSTITUTIONAL EXPERIENCE
por: Fonseca, Adriana, et al.
Publicado: (2020)

DIPG-70. DISORDERED DNA METHYLATION IN DIPG UNDERLIES PHENOTYPIC PLASTICITY
por: Koldobskiy, Michael, et al.
Publicado: (2020)

DIPG-59. UPREGULATION OF PRENATAL PONTINE ID1 SIGNALING IN DIPG
por: Harris, Micah K, et al.
Publicado: (2020)

DIPG-57. TRANSCRIPTOMIC AND PROTEOMIC ANALYSES OF DIPG RESPONSE TO ONC201
por: Sridharan, Sreepradha, et al.
Publicado: (2020)

DIPG-12. TARGETING EPIGENETIC MODIFIERS TO INDUCE IMMUNE SIGNALING IN DIPG
por: Tetens, Ashley, et al.
Publicado: (2020)

DIPG-52. Activators of the integrated stress response synergize to kill DIPG
por: Novak, Orlandi, et al.
Publicado: (2022)

DIPG-23. SINGLE CASE REPORT OF LOW DOSE RADIOTHERAPY AND CHEMOTHERAPY IN THE TREATMENT OF DIPG
por: Tseng, Chen Kan, et al.
Publicado: (2020)

DIPG-40. TARGETING MASTER REGULATOR DEPENDENCIES IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Pavisic, Jovana, et al.
Publicado: (2020)

DIPG-37. Exploring the role of the epigenetic factor H2A.Z acetylation in DIPG
por: Sanguino, Yolanda Colino, et al.
Publicado: (2022)

DIPG-56. EXPLORATION OF TUMOR/STROMA INTERACTIONS IN DIPG XENOGRAFT BY SPECIES-SPECIFIC RNA-SEQ DECONVOLUTION INDICATES A ROLE OF MICROGLIA CELL IN DIPG DEVELOPMENT
por: Merlevede, Jane, et al.
Publicado: (2020)

DIPG-28. REPEATED LOW DOSE RT FOR PEDIATRIC DIPG – LESS DISEASE BURDEN WITH COMPARABLE OUTCOMES
por: Wu, Yao Yu, et al.
Publicado: (2020)

DIPG-32. AKT SIGNALING DRIVES RESISTANCE TO ONC201 IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Jackson, Evangeline R, et al.
Publicado: (2020)

DIPG-27. Behavioral disturbances as underestimated presenting symptoms in children with Diffuse Intrinsic Pontine Glioma (DIPG)
por: Milanaccio, Claudia, et al.
Publicado: (2022)

DIPG-21. DIPG cells alter the permeability of the blood-brain barrier in the brainstem leading to treatment failure.
por: Ung, Caitlin, et al.
Publicado: (2022)

DIPG-53. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGS)
por: Khadka, Prasidda, et al.
Publicado: (2020)

DIPG-16. COMBINATION OF ARGININE DEPLETION AND POLYAMINE INHIBITION AS AN ANTICANCER STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Khan, Aaminah, et al.
Publicado: (2020)

DIPG-38. ADDITION OF MULTIMODAL IMMUNOTHERAPY TO COMBINATION TREATMENT STRATEGIES FOR CHILDREN WITH DIPG: FINAL RESULTS OF A COHORT OF CHILDREN
por: Van Gool, Stefaan, et al.
Publicado: (2020)

DIPG-13. TARGETING HYPOXIA AND MITOCHONDRIA WITH REPURPOSED METABOLIC DRUGS AS AN APPROACH TO RADIOSENSITIZATION FOR DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG)
por: Shen, Han, et al.
Publicado: (2020)

DIPG-07. HIGH THROUGHPUT DRUG SCREENING IDENTIFIES POTENTIAL NEW THERAPIES FOR DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGs)
por: Upton, Dannielle, et al.
Publicado: (2020)

DIPG-83. USING COPPER CHELATING AGENTS TO TARGET RECEPTOR TYROSINE KINASE SIGNALLING IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Michniewicz, Filip, et al.
Publicado: (2020)

DIPG-71. SELECTIVE HDAC INHIBITOR RG2833 INDUCES DIPG CELL DEATH VIA DOWNREGULATION OF THE NFĸB PATHWAY
por: Barnett, Katherine, et al.
Publicado: (2020)

DIPG-20. Copper chelation therapy targets S-adenosylmethionine (SAM) metabolism and epigenetic regulators in diffuse intrinsic pontine glioma (DIPG)
por: Michniewicz, Filip, et al.
Publicado: (2022)

DIPG-18. Evaluating drug distribution in children with diffuse intrinsic pontine glioma (DIPG) treated with convection-enhanced drug delivery
por: Szychot, Elwira, et al.
Publicado: (2022)

DIPG-02. Role of a Bevacizumab-based regime in the treatment of children with diffuse intrinsic pontine glioma (DIPG): a systematic review
por: Evans, Mia, et al.
Publicado: (2022)

DIPG-55. PATTERNS OF CEREBROSPINAL FLUID DIVERSION AND SURVIVAL IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY
por: Cooney, Tabitha, et al.
Publicado: (2020)

DIPG-49. BRAINSTEM AND PONTINE VOLUMETRIC ANALYSIS AS A SURROGATE MEASURE OF LOCAL DISEASE CONTROL IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Bander, Evan D, et al.
Publicado: (2020)

DIPG-47. TSO500ctDNA sequencing reveals oncogenic mutations and copy number variations in the liquid biome of children with diffuse midline glioma
por: Bonner, Erin R, et al.
Publicado: (2022)

DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG
por: Gardner, Sharon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uk0eg9pqf1cji28n2cmv8oeac7